When is HCC Called Non-Operable (Unresectable)?

Only 20-40% of HCC patients are candidates for surgical resection at the time of diagnosis. Inoperability is determined by two broad categories: oncological (tumor-related) and functional (liver/patient-related) factors.

1. Oncological Contraindications (Tumor Factors)

These make complete resection technically impossible or oncologically futile:

Factor	Detail
Extrahepatic metastases	Any distant spread (lung, bone, adrenal, peritoneum)
Multiple / bilobar tumors	Tumor in both lobes making adequate resection impossible
Major vascular invasion	Tumor thrombus in the main portal vein or inferior vena cava
Main bile duct involvement	Direct invasion precluding clear margins
Lymph node involvement (N1)	Regional nodal disease
Inadequate future liver remnant (FLR)	FLR <20-30% in healthy liver, <30% in steatotic/chronic hepatitis liver, <40% in cirrhotic liver

Note: Multifocal or large tumors (>5 cm) are poor prognostic indicators but not absolute contraindications - the decision requires individualized assessment.

Bailey & Love's Short Practice of Surgery, 28th Ed., p. 1235-1236
Current Surgical Therapy, 14th Ed., p. 424

2. Functional / Hepatic Contraindications (Liver Reserve)

These make the patient unable to survive surgery or the hepatic remnant unable to sustain life:

Child-Pugh Class C: Absolute contraindication to resection
Child-Pugh Class B: Major resection not feasible; minor resection possible but high risk
Child-Pugh Class A with portal hypertension: Significantly increases perioperative mortality
- Portal hypertension is defined by HVPG ≥10 mmHg, thrombocytopenia, splenomegaly, ascites, or esophageal varices
Current Surgical Therapy, 14th Ed., p. 424
Bailey & Love's, 28th Ed., p. 1235

3. Patient Performance Status

ECOG Performance Status >2: Patient cannot tolerate major surgery
Severe comorbidities that preclude safe anesthesia/surgery

BCLC Staging and Resectability

The Barcelona Clinic Liver Cancer (BCLC) system is the most widely used framework:

BCLC Staging for HCC - Current Surgical Therapy 14e

Under BCLC:

Stage	Description	Standard Treatment
0 / Very early	Single <2 cm, Child-Pugh A, PS 0	Resection (if normal portal pressure)
A / Early	Single or ≤3 nodules ≤3 cm, PS 0	Resection, transplant, or ablation
B / Intermediate	Multinodular, PS 0, no vascular invasion	TACE (not resection)
C / Advanced	Portal invasion, N1, M1, PS 1-2	Sorafenib/systemic (not resection)
D / Terminal	Child-Pugh C, PS >2	Best supportive care

Stages B, C, and D are generally considered non-operable by standard BCLC criteria. However, studies show treatment beyond BCLC guidelines (including resection for stage B) can be effective in well-selected patients.

4. Technical Unresectability

Tumor location precluding safe dissection (e.g., encasing all major hepatic veins or the confluence of the portal vein)
Inability to achieve a clear (R0) margin
Insufficient FLR volume - though preoperative portal vein embolization (PVE) can convert some patients to resectable by inducing compensatory hypertrophy of the FLR

Summary Table

Category	Criterion	Absolute vs. Relative
Extrahepatic spread	Metastasis (M1) or N1	Absolute
Main portal vein thrombus	Macrovascular invasion	Absolute
Child-Pugh C	End-stage liver disease	Absolute
Child-Pugh B	Decompensated cirrhosis	Absolute for major resection
Portal hypertension	HVPG ≥10, varices, ascites	Strong relative
Bilobar multifocal tumors	Beyond FLR capacity	Relative
ECOG PS >2	Poor performance status	Absolute
Tumor size >5 cm	Risk factor for recurrence	Relative

For patients deemed unresectable, alternatives include liver transplantation (if within Milan criteria), TACE, radiofrequency ablation, or systemic therapy (atezolizumab + bevacizumab or sorafenib).

This is a shared conversation. Sign in to Orris to start your own chat.